CXCR2 plays an important role in the activation and recruitment of neutrophils to the site of inflammation. CXCR2-IN-1 showed good central nervous system penetration characteristics (Br / Bl> 0.45)[1].

CXCR2-IN-1 has shown efficacy in oral copper ketone-induced demyelination models by oral administration, providing evidence to support CXCR2 as a potential therapeutic target for the treatment of demyelinating diseases such as multiple sclerosis[1].